Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.-MedSci.cn

Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.

Zalcman, G; Peters, S; Mansfield, AS; Jahan, TM; Popat, S; Scherpereel, A; Hu, WH; Selvaggi, G; Baas, P

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务